Sleep Disorders Pharmaceutical and Healthcare Pipeline Review 2017

Pune, India, 13th October 2017: WiseGuyReports announced addition of new report, titled “Sleep Disorders Drug Development Pipeline Review, 2017”.

Pune, India - October 13, 2017 /MarketersMedia/ —

Summary
This report provides an overview of the pipeline landscape for sleep disorders. The report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for Restless Legs Syndrome, Nocturia and Insomnia, and features dormant and discontinued projects.

Restless Legs Syndrome is a neurologic disorder with a core feature of a distressing, irresistible need or urge to move the legs. Risk factors for RLS include low iron levels, kidney failure, Parkinson's disease, diabetes mellitus, rheumatoid arthritis, and pregnancy.

GET SAMPLE REPORT @ https://www.wiseguyreports.com/sample-request/2385279-sleep-disorders-drug-development-pipeline-review-2017

Nocturia, or nocturnal polyuria, describes the excessive urination during night time. Nocturia becomes more common with age and may be symptomatic of the use of diuretic substances, prescription drugs, edema from heart failure, insomnia, pain and prostate or bladder disorders.

Finally, insomnia is a sleep disorder that is characterized by difficulty in falling or staying asleep. Symptoms include difficulty falling asleep at night, waking up during the night, irritability, depression and anxiety.

The size of these pipelines ranges from eight products in restless legs syndrome and nocturia to 31 in insomnia. Across all three of these indications there is a diverse range of molecular targets due to the different pathologies of the indications. The most common targets for restless legs syndrome, nocturia and insomnia therapeutics are D2 dopamine receptor, vasopressin V2 receptor and orexin receptor, respectively.

Scope
- Which companies are the most active within the pipeline for sleep disorder therapeutics?
- Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
- To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
- What are the most important R&D milestones and data publications to have happened in the field of sleep disorders?

Reasons to buy
- Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
- Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each
- Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these
- Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration

Table of Content: Key Points

1 Table of Contents 4
1.1 List of Tables 5
1.2 List of Figures 6
2 Introduction 7
2.1 Sleep Disorders Report Coverage 7
2.2 Restless Legs Syndrome - Overview 7
2.3 Nocturia - Overview 7
2.4 Insomnia - Overview 7
3 Therapeutics Development 8
3.1 Restless Legs Syndrome 8
3.2 Nocturia 11
3.3 Insomnia 14
4 Therapeutics Assessment 21
4.1 Restless Legs Syndrome 21
4.2 Nocturia 27
4.3 Insomnia 33
5 Companies Involved in Therapeutics Development 39
5.1 Restless Legs Syndrome 39
5.2 Nocturia 42
5.3 Insomnia 44
6 Dormant Projects 53
6.1 Restless Legs Syndrome 53
6.2 Nocturia 53
6.3 Insomnia 54
7 Discontinued Products 56
7.1 Restless Legs Syndrome 56
7.2 Insomnia 56
8 Product Development Milestones 58
8.1 Restless Legs Syndrome 58
8.2 Nocturia 63
…Continued

Get in touch:
LinkedIn: www.linkedin.com/company/4828928
Twitter: https://twitter.com/WiseGuyReports
Facebook: https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts

Contact Info:
Name: NORAH TRENT
Email: Send Email
Organization: WISEGUY RESEARCH CONSULTANTS PVT LTD
Address: Office No. 528, Amanora Chambers
Phone: +91 841 198 5042

Source URL: https://marketersmedia.com/sleep-disorders-pharmaceutical-and-healthcare-pipeline-review-2017/250082

For more information, please visit http://www.wiseguyreports.com

Source: MarketersMedia

Release ID: 250082

More News From thebudgetreport.com

Federal shutdown enters Day 2 amid blame game on both sides

Jan 21, 2018

WASHINGTON — Senate leaders offered no obvious solution to reopening the government and engaged in unrelenting finger-pointing during a rare Sunday session in the hours leading up to a vote to end the shutdown before the workweek began. The chamber's top Democrat indicated that he would continue to lead a filibuster of a stopgap spending measure that's slated for a post-midnight vote, while congressional Republicans appeared content to let the pressure continue to build on the second day of the government shutdown. Senate Democrats blocked the temporary governmentwide funding bill Friday night, demanding progress on legislation to protect about 700,000...

The Latest: German Social Dems vote to enter coalition talks

Jan 21, 2018

BERLIN — The Latest on efforts to create a new coalition government in Germany (all times local): 4:30 p.m. Germany's Social Democrats have voted to enter coalition talks with Chancellor Angela Merkel's conservatives, a key step toward ending political gridlock and forming a new government. Delegates in Bonn voted 362 to 279 on Sunday in favor of opening the coalition talks. Once a coalition agreement is reached with Merkel's Union bloc, the Social Democrats' membership still would have to approve it before a government can be formed. Ahead of the vote, party leader Martin Schulz told delegates he would push...

Iran may try to loosen Revolutionary Guard's grip on economy

Jan 21, 2018

DUBAI, United Arab Emirates — Iran's supreme leader has ordered the Revolutionary Guard to loosen its hold on the economy, the country's defense minister says, raising the possibility that the paramilitary organization might privatize some of its vast holdings. The comments this weekend by Defense Minister Gen. Amir Hatami appear to be a trial balloon to test the reaction of the idea, long pushed by Iran's President Hassan Rouhani, a relative moderate. Protests over the country's poor economy last month escalated into demonstrations directly challenging the government. But whether the Guard would agree remains unclear, as the organization is estimated...

Mick Mulvaney finds himself in middle of another shutdown

Jan 21, 2018

WASHINGTON — Mick Mulvaney stormed Washington as a tea party lawmaker elected in 2010, and he hasn't mellowed much as director of the Office of Management of Budget at the White House. In both spots, he's been at the center of a government shutdown. But this time he is arguing against it and is faulting Democrats for seeking to use the very kind of leverage he tried to utilize in 2013. Then a congressman, Mulvaney was among a faction on the hard right that bullied GOP leaders into a shutdown confrontation by insisting on lacing a must-pass spending bill with...

The Latest: Senate GOP plans a vote aimed at ending shutdown

Jan 21, 2018

WASHINGTON — The Latest on the government shutdown (all times local): 7:30 p.m. A Senate showdown vote on a Republican plan for ending the federal shutdown is on track to occur by early Monday. Democrats say they have the votes to block it. Senate Majority Leader Mitch McConnell has proposed a measure financing the government through Feb. 8. Senate Democrats derailed a House-passed measure early Saturday that would have run through Feb. 16. They say they want to provide enough money to keep agency doors open only a few days. They say the shorter time frame puts more pressure on...

The Budget Report seeks to provide comprehensive coverage and analysis on the current economic, financial issues around the world. First hand finance and economic news all day, every day.

Contact us: sales@thebudgetreport.com